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Abstract
The mucosal immune system is in constant communication with the vast diversity of microbes present on body
surfaces. The discovery of novel molecular mechanisms, which mediate host-microbe communication, have highlighted
the important roles played by microbes in influencing mucosal immune responses. Dendritic cells, epithelial cells, ILCs, T
regulatory cells, effector lymphocytes, NKT cells and B cells can all be influenced by the microbiome. Many of
the mechanisms being described are bacterial strain- or metabolite-specific. Microbial dysbiosis in the gut and
the lung is increasingly being associated with the incidence and severity of asthma. More accurate endotyping of patients
with asthma may be assisted by further analysis of the composition and metabolic activity of an individual’s microbiome.
In addition, the efficacy of specific therapeutics may be influenced by the microbiome and novel bacterial-based
therapeutics should be considered in future clinical studies.
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Background
An enormous number of microbes colonize the skin and
mucosal body surfaces. These microbes are highly
adapted to survive within complex community struc-
tures, utilizing nutrients from other microbes and/or
host processes. The microbiome is defined as the sum of
these microbes, their genomic elements and interactions
in a given ecological niche. The composition and diver-
sity of the microbiome varies across body sites, resulting
in a series of unique habitats within and between indi-
viduals that can change substantially over time [1]. The
establishment of stable microbial communities closely
tracks host growth and immune development during the
first few years of life. Factors that influence this evolu-
tion include antibiotic use, birth mode, infant nutrition
and biodiversity in the home, surrounding environment
and in family members [2]. Delayed or altered establish-
ment of these microbial communities’ leads to micro-
biome immaturity and has been associated with
increased risk of allergies and asthma later in life.
Highly sophisticated mucosal immune cellular and
molecular networks need to be constantly coordinated
in order to tolerate the presence of a large number and
diversity of bacteria, while protective immune responses
to potential pathogens must be maintained and induced
on demand. The balance between immune tolerance and
inflammation within tissues is regulated in part by the
crosstalk between immune cells and the microbiome [3].
Disrupted communication between the microbiome and
the host due to altered microbiome composition and/or
metabolism is thought to negatively influence immune
homeostatic networks. This can be clearly seen in mice
bred under germ-free (GF) or sterile conditions, whereby
mucosal tolerance mechanisms do not fully develop and
these mice display increased allergic responses to aller-
gen challenge.
In this review, we will examine the potential mechanisms
by which the microbiome influences immune responses
within the lung and assess the evidence for a dysbiotic
microbiome in the gut and the respiratory tract of asthma
patients. In addition, we will summarize the current thera-
peutic approaches and challenges associated with
microbial-based therapies in asthma patients and highlight
the future research and clinical needs in the field.
Immune mechanisms influenced by the microbiome
Multiple mechanisms have now been described, through
which bacteria can induce regulatory responses or
dampen inflammatory processes. Both bacterial cell wall
components and metabolites from the microbiome have
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been associated with immunoregulatory effects within
the mucosa. Certain commensal microbes such as spe-
cific Bifidobacterium, Lactobacillus and Clostridium
strains have been shown to increase the proportion of T
regulatory cells in mice [4–8]. In addition, Clostridia
have been shown to stimulate ILC3s to produce IL-22,
which helps to reinforce the epithelial barrier and
reduces the permeability of the intestine to dietary pro-
teins [9]. Furthermore, Bifidobacteria and Lactobacilli
can stimulate metabolic processes in dendritic cells, such
as vitamin A metabolism, tryptophan metabolism and
heme oxygenase-1, which promote induction of T regu-
latory cells [10–12]. The capsular polysaccharide A from
Bacteroides fragilis has been shown to interact directly
with mouse plasmacytoid dendritic cells and thereby
promoted IL-10 secretion from CD4+ T cells [13]. In
addition, an exopolysaccharide from Bifidobacterium
longum was recently shown to suppress Th17 responses
within the gut and within the lung [14, 15]. Notably,
consumption of Bifidobacterium longum 35,624 by
healthy human volunteers increased Foxp3+ T regula-
tory cells in peripheral blood, while administration of
this bacterial strain to psoriasis patients, chronic fatigue
syndrome patients or ulcerative colitis patients consist-
ently resulted in reduced levels of serum proinflamma-
tory biomarkers such as CRP, possibly mediated by
increased numbers of T regulatory cells [12, 16].
In addition to bacterial-associated components,
bacterial-derived metabolites have significant effects on
immunoregulatory processes. Short-chain fatty acids
(SCFAs), such as acetate, propionate and butyrate, are
produced by the gut microbiota and have been shown to
influence dendritic cell and T cell responses, via their
binding to G protein-coupled receptors and their inhib-
ition of histone deacetylases, thereby promoting epigen-
etic changes [17]. Bacteria within the human gut can
produce a wide range of biogenic amines (due to metab-
olism of amino acids), which can also influence immune
and inflammatory responses [18]. Interestingly, in
murine models, microbiota-derived taurine, histamine,
and spermine were shown to influence host-microbiome
interactions by co-modulating NLRP6 inflammasome
signaling, epithelial IL-18 secretion, and downstream
anti-microbial peptide secretion [19].
Microbiome in animal models of asthma
A number of different animal studies support the con-
cept for a role of the microbiome in development of
airway diseases. In particular, valuable insights for the
mechanistic role of the microbiome in the development
of allergic airway inflammation comes from GF animals,
lacking any exposure to pathogenic or nonpathogenic
microorganisms. Herbst et al. observed that OVA-
induced type 2 airway inflammation and airway
hypersensitivity is much stronger in GF mice as com-
pared to the mice from a specific pathogen-free environ-
ment (SPF) that were colonized with commensal
microbes. Moreover, the exaggerated allergic inflamma-
tion in GF mice could be reduced to the same level
observed in SPF mice, when GF mice were co-housed
for 3 weeks with SPF mice, suggesting that gut and
airways recolonization with commensal microbes had
protective effects [20]. In addition, early life colonization
of GF mice prevented invariant natural killer T cell accu-
mulation in the gut lamina propria and the lungs
thereby reducing the severity of allergic airway re-
sponses. Later life colonization had no effect on disease
phenotypes nor on the development of regulatory T cells
or on invariant natural killer T cells [21]. Furthermore,
antibiotic treatment of neonatal mice resulted in fewer
regulatory T cells and a more pronounced T helper cell
type 2 response, which was prevented by re-introducing
a commensal intestinal microbiota [22–24].
Gollwitzer et al. examined the susceptibility to house
dust mite (HDM)-induced allergic airway inflammation
in mice of different ages (3, 15 and 60 days), simulating
the conditions of gradual colonisation of the human
infant airways [25]. Neonatal mice were prone to de-
velop exaggerated airway eosinophilia, they released
more type 2 cytokines and exhibited higher airway
hyper-responsiveness following exposure to HDM com-
pared to mice that were older. This protective effect in
older mice was associated with the colonization of the
mouse lungs with increased numbers of bacteria and the
shift from a predominance of Gammaproteobacteria and
Firmicutes to Bacteroidetes. The maturation of the lung
microbiota was associated with the PDL-1-dependent
emergence of Helios-negative T regulatory cells. This
study suggests that the absence of specific bacterial
species early in life could influence appropriate
regulatory mechanisms later in life and subsequently
shift the immunological balance towards allergy instead
of tolerance [25].
Oral supplementation of mice with specific microbes
such as Bifidobacterium breve, Clostridium clade IV and
XIV species, or with the capsular polysaccharide PSA of
Bacteroides fragilis induced an anti-inflammatory re-
sponse associated with induction of regulatory T cells
and IL-10 secretion that attenuated allergic airway in-
flammation [21, 26]. In addition to the gut-induced
regulatory T cells that could migrate to the lungs to pro-
vide anti-inflammatory effects, there are metabolites
produced by the microbiome such as SCFAs that are
absorbed and potentially have direct effects on lung im-
mune responses [27]. Deliberate administration of
SCFAs, or dietary fibers that are metabolized to SCFAs,
has repeatedly been shown to reduce airway inflamma-
tion in murine models. A high-fiber diet increased the
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level of colonic Bacteroidetes and Actinobacteria species
and decreased Firmicutes and Proteobacteria, which was
associated with increased SCFA serum levels and sup-
pression of allergic airway-inflammation in mice [28].
The beneficial effect was transferred to the offspring
after treatment of pregnant mice via epigenetic mecha-
nisms [26, 29]. The influence of the microbiota on D-
tryptophan, Vitamin A or biogenic amine metabolism
can also modulate T helper cell type 2 mediated allergic
airway inflammation within the lung [3, 26, 30, 31].
Several studies have suggested that direct exposure of
the murine respiratory tract to microbial products such as
endotoxin, CpG-containing oligonucleotides or other
Toll-like receptor ligands could inhibit the classical fea-
tures of asthma [32, 33]. For example, intranasal exposure
to the bacterium Escherichia coli was protective in the
OVA-induced allergic airway inflammation model [34].
These studies were recently expanded by novel findings
that linked the protective effect of the farm environment
with the microbiota and endotoxin levels in the house
dust. Schuijs et al. demonstrated that prolonged exposure
to low-dose endotoxin or farm dust protected mice from
HDM-induced asthma via A20 (TNFAIP3)-dependent air-
way epithelial cells-dendritic cells interactions [35]. Stein
et al. further demonstrated that intranasal installation of
the dust from Amish houses, but not dust from Hutterite
homes, reduced OVA-induced allergic airway inflamma-
tion in mice, via Myd88 and Trif-dependent mechanisms
[36]. The dust from the Amish homes had different
bacterial populations (especially higher in Bartonellaceae)
and higher endotoxin levels as compared to Hutterite
houses’ dust [36].
The role of the gut microbiome in asthma
The human gut microbiome is the largest collection of
bacteria in the body, consisting of 500–1000 distinct
bacterial species with more than 8 million genes poten-
tially influencing the host immune system [21, 37]. Euro-
pean adults’ gut microbiota is predominantly colonized
by Bacteroidetes, Firmicutes, Actinobacteria, Proteobac-
teria, and Verrucomicrobia. The stomach, duodenum,
and proximal small intestine are mainly colonized with
aerobic bacteria including Streptococci species, Lactoba-
cilli species, and Enterobacteriaceae while anaerobes
such as Bacteroides, Bifidobacterium, Prevotellaceae,
Rikenellaceae, Lachnospiraceae, Ruminococcaceae, and
Clostridium species dominate the distal small intestine
and the colon [26, 38]. The gut microbiota can influence
immune responses at distant sites (such as the lung) via
multiple mechanisms. For example, it was recently
shown that there is an increase in the number of bac-
teria capable of secreting histamine from the gut of adult
asthma patients, compared to healthy volunteers [39].
However, it is not clear if increased secretion of
histamine by gut microbes can have an overall detrimen-
tal or protective effect as histamine can induce protect-
ive responses in the lung via histamine 2 receptor and
detrimental effects via histamine 1 and 4 receptors [40].
The composition of the gut microbiome is thought to
reach an adult-like diversity by 3 years of age. Develop-
ment of the early life gut microbiome is influenced by
many environmental factors, such as living in microbial
rich environments (e.g. on a farm or with frequent contact
to livestock and pets), or a diverse diet, which have been
inversely associated with childhood asthma [41–45]. It is
thought that exposure to and colonization by certain mi-
crobes at the correct time during early life is important for
gut development, immune cell maturation and resistance
to pathogens, all of which may protect against the devel-
opment of asthma [22, 37, 46]. The mode of delivery has a
significant influence on colonization. Babies delivered via
caesarean section typically have more Staphylococcus spe-
cies, Bacillales, Propionobacterineae, Corynebacterineae,
Firmicutes and Acinetobacter species with fewer Actino-
bacteria and Bacteroidetes, while vaginal delivery has been
linked to increased colonization with Clostridia [38, 47].
Clostridia metabolize fibers to SCFAs, which can have
systemic anti-inflammatory effects as described above. In
addition to delivery mode and diet, maternal antibiotic
use during pregnancy or antibiotic treatment in early
childhood significantly disrupts the microbiota and was
associated with long-lasting effects such as decreased
Actinobacteria and increased Bacteroidetes and Proteo-
bacteria [1].
Several studies have linked early life dysbiosis of the
gut microbiota with an altered risk of asthma later in
life. Colonization by Clostridium difficile at 1 month of
age was associated with wheeze throughout the first 6 to
7 years of life and with asthma at age 6 to 7 years [48].
Children that developed asthma at school age, had a
lower gut microbiome diversity at 1 week or 1 month of
age, but not at 1 year of age, compared to non-asthmatic
children [49]. In another study, the early life relative
abundance of the bacterial genera Lachnospira, Veillo-
nella, Faecalibacterium, and Rothia was significantly
decreased in children at risk of asthma. This dysbiosis
was accompanied by reduced levels of fecal acetate and
dysregulation of enterohepatic metabolites [50]. In
addition, neonates with the lowest relative abundance of
Bifidobacteria, Akkermansia and Faecalibacterium and a
higher relative abundance of particular fungi (Candida
and Rhodotorula), had the highest risk to develop atopy
and asthma [51]. Thus, early life dysbiosis of the gut
microbiota has been consistently associated with an in-
creased risk of asthma later in life. However, it remains
unclear if microbial dysbiosis within the gut can actually
drive relevant disease promoting mechanisms or if dys-
biosis simply reflects associated phenomena such as
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altered patterns of immune response to microbes and
environmental stimuli.
Role of the respiratory microbiome in asthma
The Human Microbiome Project, launched in 2007, did
not include airway tissue sampling as healthy human
lung tissue at that time was assumed to be sterile [52].
However, shortly afterwards a number of pioneering
publications in this field appeared and several research
consortia and individual groups subsequently started in-
tensive studies to characterize and understand the com-
position and function of airway microbiota in health and
disease [53–55]. Currently, it is known that the healthy
respiratory mucosa is inhabited by niche-specific bacter-
ial communities [56]. The highest densities of bacterial
communities are found in the upper respiratory tract,
reaching up to 103 viable bacteria per nasal swab from
the nasal cavity and nasopharynx, with even up to 106/
ml viable cells from oropharynx lavages [56–58]. In the
trachea and lungs, the estimated numbers of bacteria are
lower with approximately 102 bacterial cells per ml being
found in bronchoalveolar lavages (BAL) from healthy
lungs [59]. The six dominant phyla routinely found in
the lung are Firmicutes, Proteobacteria, Bacteroides,
Fusobacteria, Acidobacteria, and Actinobacteria [60].
The original proof-of-concept study from Hilty et al.,
with microbiome assessments of the nose, oropharynx,
bronchial brushings and BAL samples from the lower
airways revealed that the Proteobacteria phylum and es-
pecially Haemophilus species are more often present in
upper and lower airways of asthmatic and COPD adults
and asthmatic children [53]. The study performed by
Huang et al. in patients with suboptimal controlled
asthma, defined as persistent symptoms on the Asthma
Control Questionnaire after 4 weeks of standardized
treatment with inhaled fluticasone, showed a greater air-
way microbiota diversity in these patients compared to
control subjects that correlated positively with bronchial
hyperresponsiveness [61]. Specifically, there was an
increase in the phylum Proteobacteria in asthma
patients, including Comamonadaceae, Sphingomonada-
ceae, Nitrosomonadaceae, Oxalobacteraceae, and Pseu-
domonadaceae families [61]. Interestingly, adult patients
who benefited most from clarithromycin treatment, as
assessed by the reduction in bronchial hyperactivity to
methacholine were those who had significantly greater
bacterial diversity prior the intervention [61]. Subse-
quent studies also confirmed that Proteobacteria were
present in higher proportions in the asthmatic airways
[59, 62]. In addition, Klebsiella species were enriched in
patients with severe asthma as compared to patients
with mild-to-moderate asthma and controls [63]. More-
over, within severe asthma patients, Proteobacteria was
associated with TH17-related gene signature in airway
epithelium, worsening asthma control and total leuco-
cytes in the sputum, while Bacteroides/Firmicutes were
more abundant in obese patients with severe asthma. In
contrast, the presence of Actinobacteria correlated with
improvement and/or no change in asthma control [63].
Severe asthma had long been associated with the pres-
ence of Mycoplasma pneumoniae and Chlamydophila
pneumoniae, resulting in several clinical trials with
macrolide antibiotics in this group of patients [64]. Yet,
in the face of controversial study results and the possi-
bility that beneficial microbial species are also affected,
further clinical trials that include detailed microbiome
studies are needed [65, 66].
The composition of the airway microbiome develops ex-
ponentially very early in life and later in life can be influ-
enced by the environment, health status and age. Birth
mode (vaginal or via caesarean section), the exposures
during the first hours of life and the environment of the
following 3–4 months of life have been shown to be of
utmost importance in shaping the development of stable
respiratory and gut microbiota to ensure respiratory
health later in life [50, 67–69]. Both human and animal
studies have shown that inhaled dust particles can carry a
complex mixture of microbes and microbial factors, which
influence susceptibility to asthma development via their
effects on innate and adaptive immune responses [35, 36].
The important research questions that are currently being
addressed in children include: i) what is the longitudinal
process of upper airways colonization in healthy infants?
ii) how do environmental factors such as breast feeding,
living on a farm, number of siblings, day-care, pets at
home, smoking and antibiotic usage impact the respira-
tory microbiome? iii) are there correlations between pat-
terns of respiratory microbial colonization in early life
with the occurrence of acute respiratory infections such as
respiratory syncytial virus (RSV), rhinovirus and influenza
virus and their further impact on chronic non infectious-
associated recurrent wheeze, atopic sensitization and
asthma? [58, 70–74].
Teo et al. analyzed the nasopharynx microbiome in a
prospective cohort of children at several time-points up
to 2 years of age and correlated the presence of specific
groups of bacteria with acute respiratory infections [68].
Healthy infants from this cohort were initially colonized
with Staphylococcus or Corynebacterium species up to
2 months of age with subsequent stable colonization by
Allociococcus or Moraxella. In contrast, Streptococcus,
Moraxella or Haemophilus colonization were correlated
with virus-associated acute respiratory infections in the
first 60 weeks of life. Early asymptomatic Streptococcus
colonization, rare in children from dog and cat-owning
families, increased the risk of asthma at 5 years of age
[68]. Early upper respiratory tract colonization with S.
pneumoniae, H. influenzae and/or M. catarrhalis in
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children at 4 weeks of age from other prospective birth
cohorts was also found to be associated with an
increased risk of pneumonia and bronchiolitis or asthma
at 5 years of age [54, 75]. Additional studies have also
noted associations between H. influenza, Streptococcus
species and S. aureus nasopharyngeal colonization with
RSV infection and hospitalization in children independ-
ently of their age [76–78]. Furthermore, early
colonization of the upper respiratory tract of healthy in-
fants with Staphylococcus species, subsequently followed
by Corynbactrium/Dolosigranulum and Moraxella, were
described for infants who were breastfed and who had
lower rates of respiratory infections in the first 2 years of
life [67, 79, 80]. Indeed, airway microbial diversity ap-
pears to be inversely associated with sensitization to
house dust mites in early childhood [81, 82]. Of particu-
lar interest is a recent study comparing Amish children
raised on traditional farms, who have a low prevalence
of asthma and atopy, with Hutterite children coming
from highly industrialized farms who have a higher
prevalence of asthma and atopy, even though these two
populations are genetically similar. One striking differ-
ence was the microbial composition and endotoxin load
of dust from those two housing environments, associ-
ated with the enhanced induction of innate immune
pathways in Amish children. The high-endotoxin dust
from Amish houses was able to inhibit OVA-induced al-
lergic airway inflammation in mice, as described above
[36]. Several other studies have also confirmed that the
farm environment is associated with increased bacterial
diversity in the house dust samples and nasal micro-
biome diversity of the same children who have lower risk
of developing asthma [83–85]. It is currently unknown if
the protective effect of the dust-associated microbiome
is due to inhalation of multiple bacteria species and fur-
ther colonization of the airways, or if inhaled bacterial
metabolites may also play a role.
Microbiome strategies for asthma prevention, treatment
and management
Alterations in the lung and gut microbiome of asthma
patients have been well described previously in this
review. The deliberate restoration of lung and gut micro-
biota through the use of prebiotics; probiotics or synbio-
tics is one potential strategy currently being assessed.
Interest in probiotics and prebiotics for their potential
benefits in protecting against airway inflammation is
relatively recent but increasing significantly, particularly
as several lines of evidence suggest that a “healthy”
microbial community facilitates the development of im-
mune tolerance [30]. In vitro studies and animal models
have repeatedly shown the protective effects of certain
probiotic strains on lung inflammatory responses, but
have also shown that not all probiotics will induce the
same effects [86]. Intervention and prevention studies in
humans are inconsistent in their findings, possibly be-
cause many factors complicate the analysis of dysbiosis
in patients with asthma. Comparison between human
studies are difficult, because of considerable heterogen-
eity in the probiotics and/or prebiotics used, study
design, sample size, age of study population, geographic
location and lifestyle factors (including diet). One pre-
liminary study did suggest that symbiotic (pre and pro-
biotic) use improved peak expiratory flow and reduced
the systemic production of Th2 cytokines in allergic
asthmatics [87]. Another recent study using a combin-
ation of nutritional interventions (fish oils and vegetable
extracts) with a probiotic led to significant improvement
in pulmonary function parameters and significantly
reduced requirement for short-acting inhaled bronchodi-
lators and inhaled corticosteroids in children with
asthma, suggesting that the combination of multiple ap-
proaches may lead to the most optimal benefits [88].
These findings are promising, however more definitive
studies are needed to determine whether modification of
gut and lung microbiota can be attributed to pre and/or
probiotic use. Currently, there is no recommendation to
use pre- or probiotics for treatment or prevention of
asthma. Nevertheless, there is accumulating evidence
that antenatal interactions between maternal diet, gut
bacteria and bacterial metabolites may lead to immuno-
logical imprinting on the developing fetal immune
system that could influence the development of allergy
and asthma later in life [89]. Thus, further studies are
required to determine if appropriate prebiotic and pro-
biotic use during pregnancy may functionally impact the
maternal gut microbiome with subsequent effects on
maternal immune function and risk of asthma in the
offspring [90].
In addition to using single probiotic bacterial strains, the
manipulation of the entire gut microbiome with fecal
microbiota transplants (FMT) is currently being explored.
FMT has been successfully used for the treatment of Clos-
tridium difficile infection and research into its use for other
inflammatory diseases such as type 2 diabetes, inflamma-
tory bowel diseases and non-alcoholic steatohepatitis is
well under way [91]. The use of FMT beyond intestinal dis-
orders requires additional studies and currently there is no
data supporting its use in allergic disease or asthma [1].
The role of the microbiome in influencing precision
medicine approaches to patient care has been best explored
to date in the oncology field. Accumulating evidence sug-
gests that the microbiome not only influences the severity
of treatment-associated side effects in cancer patients, but
also has a dramatic effect on treatment efficacy via pharma-
codynamic and immunological mechanisms [92]. Notably,
a melanoma mouse model showed commensal microbe-
derived antitumor immunity evidenced by higher
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intratumoral CD8+ T cell accumulation. From this micro-
biota, Bifidobacteria were identified as having the strongest
association with antitumor T cell immunity and the ability
to maximize the efficacy of the cancer immunotherapeutic
anti-PD-L1-specific antibody treatment. Bifidobacteria aug-
mented dendritic cell function leading to enhanced CD8+
T cell priming and accumulation within the tumor [93].
While there is a growing amount of data on the compos-
itional differences in lung microbiota in health and disease,
there is a dearth of research into the functional role of the
microbiome on treatment efficacy in patients with chronic
respiratory disorders [94]. One important study did correl-
ate corticosteroid use and corticosteroid sensitivity in
asthma patients with the presence of specific microbes in
the lower airways. At the genus level, Neisseria species,
Haemophilus species, Campylobacter species and Leptotri-
chia species were present in the lower airways of patients
with corticosteroid-resistant asthma, but not in patients
with corticosteroid-sensitive asthma [59]. Others have dem-
onstrated that corticosteroid use, particularly the combin-
ation of inhaled and oral corticosteroids, is associated with
an increased abundance of Proteobacteria and the genus
Pseudomonas, and decreased abundance of Bacteroidetes,
Fusobacteria, and Prevotella species [60]. One recent study
suggests that microbiome-related functions might affect re-
sponsiveness to corticosteroid treatment in asthma patients
[95]. Pre-steroid treatment Haemophilus levels were in-
creased in asthma patients with diminished responses to
corticosteroids. Furthermore, the predicted metagenome
metabolic functions in inhaled corticosteroid nonre-
sponders suggested increased microbiome-associated xeno-
biotic degradation capacity [95].
Further profiling and characterization of the micro-
biome associated with different asthma phenotypes is
necessary for identifying novel microbiota-related mech-
anisms of disease. In addition, identification of these key
microbial species and their associated functional effects
will contribute to a more precise definition of asthma
phenotypes and may help identify more suitable “pheno-
type-specific” management strategies [96].
Future perspectives
While it is clear that the microbiome significantly influ-
ences host immune maturation and immune activity, the
molecular basis for these immunomodulatory mecha-
nisms are only beginning to be elucidated. It still
remains unclear whether and, if so, to what extent pat-
terns of airway microbial dysbiosis actually drives rather
than merely reflects associated patterns of immune re-
activity within the lung. Current studies in prospective
birth cohorts and cross-sectional studies in children
have heightened our awareness of time-sensitive patterns
of colonization of seemingly protective or detrimental
bacteria in the gut or airways of healthy and diseased
children. However, further mechanistic and epidemio-
logical studies are needed to uncover the functional,
multidirectional associations between the specific bacter-
ial strains, host, allergens and viruses. Respiratory micro-
biome assessments in adults have so far been performed
in a cross-sectional manner, comparing the airway
microbiota composition between healthy controls and
patients with asthma and often with other chronic
airway diseases. Some studies have provided detailed
clinical characteristics of patients, allowing for the cor-
relation of microbiota differences across different asthma
phenotypes. However, longitudinal and prospective ana-
lyses of adult airway microbiome in bigger cohorts of
well-characterized patients are still needed to under-
stand the relationships between the course of the
disease, its phenotype and endotype, susceptibility to
exacerbations and disease progression as well as its
response to treatment.
Compositional profiling needs to be complemented
with metagenomics, transcriptomics, physiological, bio-
chemical and function-oriented analyses of both the host
response and microbial communities as interactions
between the host and microbiome are almost certainly
bidirectional, with species- and strain-specific behaviors
shaped by the genetic background and microenviron-
ment in which they exist. In addition, current compos-
itional analysis at the genus level is not sufficient and
future analysis needs to be conducted at greater depth to
include information at the species and strain level. The
immune response to a bacterium is often strain-specific
and results from one strain cannot be extrapolated to
other strains even within the same species. Thus, the
traditional methods for microbiological classification,
based on 16 s sequencing and certain biochemical prop-
erties, of a bacterium into a given genus or species do
not currently help us to predict immunological out-
comes. Culturing methods need also to be improved in
order to isolate and grow lung-derived bacterial strains
in vitro, particularly the obligate anaerobes, in order to
facilitate strain-specific immunological assessments.
Conclusions
The last few years have resulted in pivotal studies that
clearly associate changes in gut or lung microbial popu-
lations with asthma. However, mechanistic studies are
still necessary to elucidate how members of the micro-
biota induce or modulate inflammatory responses in
asthmatic patients. We anticipate that the continuing
identification of novel bacterial strains, their compo-
nents and metabolites, which modulate mucosal immu-
noregulatory responses, will open up new possibilities
for a bug-to-drug approach in the treatment of asthma
patients and the prevention of airway diseases.
Sokolowska et al. Asthma Research and Practice  (2018) 4:1 Page 6 of 9
Abbreviations
BAL: Bronchoalveolar lavages; FMT: Fecal microbiota transplant; GF: Germ-
free; HDM: House dust mite; NLRP6: NOD-like receptor family pyrin domain
containing 6; RSV: Respiratory syncytial virus; SCFAs: Short-chain fatty acids;
SPF: Specific pathogen-free
Acknowledgements
None
Funding
The authors are supported by Swiss National Science Foundation grants
(project numbers CRSII3_154488, 310,030_144219, 310,030–127,356 and
310,030_144219) and Christine Kühne – Center for Allergy Research and
Education (CK-CARE).
Availability of data and materials
Not applicable
Authors’ contributions
All authors contributed to the writing of the review. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
LOM is a consultant to Alimentary Health Ltd. and has received research
funding from GlaxoSmithKline. CA has received research support from
Novartis and Stallergenes and consulted for Actellion, Aventis and
Allergopharma. MS, RF and NL have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Swiss Institute of Allergy and Asthma Research, University of Zürich, Obere
Strasse 22, 7270 Davos, Switzerland. 2Christine Kühne – Center for Allergy
Research and Education (CK-CARE), Davos, Switzerland. 3University of Cape
Town, Cape Town, South Africa.
Received: 14 September 2017 Accepted: 18 December 2017
References
1. Huang Y, Marsland B, Bunyavanich S, O'Mahony L, Leung D, Muraro A, et al.
(2017). The microbiome in allergic disease: current understanding and
future opportunities—2017 PRACTALL document of the American Academy
of Allergy, Asthma & Immunology and the European academy of allergy
and clinical immunology. J Allergy Clin Immunol. 2017;139:1099–110.
2. Bokulich N, Chung J, Battaglia T, Henderson N, Jay M, Li H, et al. Antibiotics,
birth mode, and diet shape microbiome maturation during early life. Sci
Transl Med 2016;8:343-43.
3. Frei R, Lauener R, Crameri R, O'Mahony L. Microbiota and dietary
interactions - an update to the hygiene hypothesis? Allergy. 2012;67:451–61.
4. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al. Treg
induction by a rationally selected mixture of clostridia strains from the
human microbiota. Nature. 2013;500:232–6.
5. O'Mahony C, Scully P, O'Mahony D, Murphy S, O’Brien F, Lyons A, et al.
Commensal-induced regulatory T cells mediate protection against
pathogen-stimulated NF-kappaB activation. PLoS Pathog. 2008;4:e1000112.
6. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M.
Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing
IL-10 and IL-10- dependent TGF-β-bearing regulatory cells. J Immunol.
2005;174:3237–46.
7. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced
regulatory T cells protect against an allergic airway response in mice. Am J
Respir Crit Care Med. 2009;179:186–93.
8. Tang C, Kamiya T, Liu Y, Kadoki M, Kakuta S, Oshima K, et al. Inhibition
of Dectin-1 signaling ameliorates colitis by inducing lactobacillus-
mediated regulatory T cell expansion in the intestine. Cell Host
Microbe. 2015;18:183–97.
9. Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, et al.
Commensal bacteria protect against food allergen sensitization. Proc Natl
Acad Sci U S A. 2014;111:13145–50.
10. Konieczna P, Ferstl R, Ziegler M, Frei R, Nehrbass D, Lauener RP, et al.
Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina
propria requires retinoic acid-dependent and independent mechanisms.
PLoS One. 2013;8:e62617.
11. Karimi K, Kandiah N, Chau J, Bienenstock J, Forsythe PA. Lactobacillus
rhamnosus strain induces a heme oxygenase dependent increase in Foxp3
+ regulatory T cells. PLoS One. 2012;7:e47556.
12. Konieczna P, Groeger D, Ziegler M, Frei R, Ferstl R, Shanahan F, et al.
Bifidobacterium infantis35624 administration induces Foxp3 T regulatory
cells in human peripheral blood: potential role for myeloid and
plasmacytoid dendritic cells. Gut. 2011;61:354–66.
13. Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker H, Kasper D.
Plasmacytoid Dendritic cells mediate anti-inflammatory responses to a gut
Commensal molecule via both innate and adaptive mechanisms. Cell Host
Microbe. 2014;15:413–23.
14. Schiavi E, Gleinser M, Molloy E, Groeger D, Frei R, Ferstl R, et al. The surface-
associated exopolysaccharide of Bifidobacterium longum 35624 plays an
essential role in dampening host Proinflammatory responses and repressing
local T H 17 responses. Appl Environ Microbiol. 2016;82:7185–96.
15. Altmann F, Kosma P, O'Callaghan A, Leahy S, Bottacini F, Molloy E, et
al. Genome analysis and characterisation of the exopolysaccharide
produced by Bifidobacterium longum subsp. longum 35624™. PLoS
One. 2016;11:e0162983.
16. Groeger D, O’Mahony L, Murphy E, Bourke J, Dinan T, Kiely B, et al.
Bifidobacterium infantis35624 modulates host inflammatory processes
beyond the gut. Gut Microbes. 2013;4:325–39.
17. Smolinska S, Groeger D, O'Mahony L. Biology of the microbiome 1:
interactions with the host immune response. Gastroenterol Clin N Am.
2017;46:19–35.
18. Pugin B, Barcik W, Westermann P, Heider A, Wawrzyniak M, Hellings P,
et al. A wide diversity of bacteria produce and degrade biogenic
amines within the human gastrointestinal tract. Microb Ecol Health Dis.
2017;28:1353881.
19. Levy M, Thaiss C, Zeevi D, Dohnalová L, Zilberman-Schapira G, Mahdi J, et al.
Microbiota-modulated metabolites shape the intestinal microenvironment by
regulating NLRP6 Inflammasome signaling. Cell. 2015;163:1428–43.
20. Herbst T, Sichelstiel A, Schär C, Yadava K, Bürki K, Cahenzli J, et al.
Dysregulation of allergic airway inflammation in the absence of microbial
colonization. Am J Respir Crit Care Med. 2011;184:198–205.
21. Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging
relationship with the gut microbiome. Cell Host Microbe. 2015;17:592–602.
22. Rook GA, Adams V, Hunt J, Palmer R, Martinelli R, Brunet LR.
Mycobacteria and other environmental organisms as
immunomodulators for immunoregulatory disorders. Springer Semin
Immunopathol. 2004;25:237–55.
23. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of
intestinal bacterial flora for the development of an IgE production system
fully susceptible to oral tolerance induction. J Immunol. 1997;159:1739–45.
24. Sudo N, XN Y, Aiba Y, Oyama N, Sonoda J, Koga Y, et al. An oral
introduction of intestinal bacteria prevents the development of a long-term
Th2-skewed immunological memory induced by neonatal antibiotic
treatment in mice. Clin Exp Allergy. 2002;32:1112–6.
25. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, et
al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1.
Nat Med. 2014;20:642–7.
26. McAleer JP, Kolls JK. Contributions of the intestinal microbiome in lung
immunity. Eur J Immunol. 2017;doi:https://doi.org/10.1002/eji.201646721.
[Epub ahead of print].
27. Natarajan N, Pluznick JL. From microbe to man: the role of microbial short
chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol.
2014;307:C979–85.
28. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru
C, et al. Gut microbiota metabolism of dietary fiber influences allergic
airway disease and hematopoiesis. Nat Med. 2014;20:159–66.
Sokolowska et al. Asthma Research and Practice  (2018) 4:1 Page 7 of 9
29. Thorburn AN, McKenzie CI, Shen S, Stanley D, Macia L, Mason LJ, et al.
Evidence that asthma is a developmental origin disease influenced by
maternal diet and bacterial metabolites. Nat Commun. 2015;6:7320.
30. Frei R, Akdis M, O'Mahony L. Prebiotics, probiotics, synbiotics, and the
immune system: experimental data and clinical evidence. Curr Opin
Gastroenterol. 2015;31:153–8.
31. Frei R, Ferstl R, Konieczna P, Ziegler M, Simon T, Rugeles TM, et al. Histamine
receptor 2 modifies dendritic cell responses to microbial ligands. J Allergy
Clin Immunol. 2013;132:194–204.
32. Rodríguez D, Keller AC, Faquim-Mauro EL, de Macedo MS, Cunha FQ, Lefort
J, et al. Bacterial lipopolysaccharide signaling through toll-like receptor 4
suppresses asthma-like responses via nitric oxide synthase 2 activity. J
Immunol. 2003;171:1001–8.
33. Kline JN. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am
Thorac Soc. 2007;4:283–8.
34. Nembrini C, Sichelstiel A, Kisielow J, Kurrer M, Kopf M, Marsland BJ.
Bacterial-induced protection against allergic inflammation through a
multicomponent immunoregulatory mechanism. Thorax. 2011;66:755–63.
35. Schuijs MJ, Willart MA, Vergote K, Gras D, Deswarte K, Ege MJ, et al. Farm
dust and endotoxin protect against allergy through A20 induction in lung
epithelial cells. Science. 2015;349:1106–10.
36. Stein MM, Hrusch CL, Gozdz J, Igartua C, Pivniouk V, Murray SE, et al. Innate
immunity and asthma risk in Amish and Hutterite farm children. N Engl J
Med. 2016;375:411–21.
37. Funkhouser LJ, Bordenstein SR. Mom knows best: the universality of
maternal microbial transmission. PLoS Biol. 2013;11:e1001631.
38. Shukla SD, Budden KF, Neal R, Hansbro PM. Microbiome effects on
immunity, health and disease in the lung. Clin Transl Immunol. 2017;
6:e133.
39. Barcik W, Pugin B, Westermann P, Perez NR, Ferstl R, Wawrzyniak M, et al.
Histamine-secreting microbes are increased in the gut of adult asthma
patients. J Allergy Clin Immunol. 2016;138:1491–4.
40. Ferstl R, Frei R, Barcik W, Schiavi E, Wanke K, Ziegler M, et al. Histamine
receptor 2 modifies iNKT cell activity within the inflamed lung. Allergy. 2017;
72:1925–35.
41. Huang YJ, Boushey HA. The microbiome in asthma. J Allergy Clin Immunol.
2015;135:25–30.
42. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, et al.
Environmental exposure to endotoxin and its relation to asthma in school-
age children. N Engl J Med. 2002;347:869–77.
43. Roduit C, Frei R, Depner M, Schaub B, Loss G, Genuneit J, et al. Increased
food diversity in the first year of life is inversely associated with allergic
diseases. J Allergy Clin Immunol. 2014;133:1056–64.
44. Frei R, Roduit C, Bieli C, Loeliger S, Waser M, Scheynius A, et al. Expression
of genes related to anti-inflammatory pathways are modified among
farmers’ children. PLoS One. 2014;9:e91097.
45. Frei R, Ferstl R, Roduit C, Ziegler M, Schiavi E, Barcik W, et al. Exposure to
nonmicrobial N-glycolylneuraminicacid protects farmers’ children against
airway inflammation and colitis. J Allergy Clin Immunol. 2017;S0091-
6749(17)30994-6. doi:https://doi.org/10.1016/j.jaci.2017.04.051. [Epub ahead
of print].
46. Weiss ST, Litonjua AA, Vitamin D. The gut microbiome, and the hygiene
hypothesis. How does asthma begin? Am J Respir Crit Care Med. 2015;191:492–3.
47. Rusconi F, Zugna D, Annesi-Maesano I, Baiz N, Barros H, Correia S, et al.
Mode of delivery and asthma at school age in 9 European birth cohorts.
Am J Epidemiol. 2017;185:465–73.
48. van Nimwegen FA, Penders J, Stobberingh EE, Postma DS, Koppelman
GH, Kerkhof M, et al. Mode and place of delivery, gastrointestinal
microbiota, and their influence on asthma and atopy. J Allergy Clin
Immunol. 2011;128:948–55.
49. Abrahamsson T, Jakobsson H, Andersson A, Björkstén B, Engstrand L,
Jenmalm M. Low gut microbiota diversity in early infancy precedes asthma
at school age. Clin Exp Allergy. 2014;44:842–50.
50. Arrieta M, Stiemsma L, Dimitriu P, Thorson L, Russell S, Yurist-Doutsch S, et
al. Early infancy microbial and metabolic alterations affect risk of childhood
asthma. Sci Transl Med. 2015;7:307ra152.
51. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosh D, et al.
Neonatal gut microbiota associates with childhood multisensitized atopy
and T cell differentiation. Nat Med. 2016;22:1187–91.
52. Human Microbiome Project, C. Structure, function and diversity of the
healthy human microbiome. Nature. 2012;486:207–14.
53. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered
microbial communities in asthmatic airways. PLoS One. 2010;5:e8578.
54. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bønnelykke K,
et al. Childhood asthma after bacterial colonization of the airway in
neonates. N Engl J Med. 2007;357:1487–95.
55. Huang YJ, Charlson ES, Collman RG, Colombini-Hatch S, Martinez FD, Senior
RM. The role of the lung microbiome in health and disease. A National
Heart, Lung, and Blood Institute workshop report. Am J Respir Crit Care
Med. 2013;187:1382–7.
56. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young
VB, et al. Analysis of the upper respiratory tract microbiotas as the source of
the lung and gastric microbiotas in healthy individuals. MBio. 2015;6:e00037.
57. Charlson ES, Diamond JM, Bittinger K, Fitzgerald AS, Yadav A, Haas AR,
et al. Lung-enriched organisms and aberrant bacterial and fungal
respiratory microbiota after lung transplant. Am J Respir Crit Care Med.
2012;186:536–45.
58. Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the
respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol.
2017;15:259–70.
59. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, et al.
The effects of airway microbiome on corticosteroid responsiveness in
asthma. Am J Respir Crit Care Med. 2013;188:1193–201.
60. Denner DR, Sangwan N, Becker JB, Hogarth DK, Oldham J, Castillo J, et al.
Corticosteroid therapy and airflow obstruction influence the bronchial
microbiome, which is distinct from that of bronchoalveolar lavage in
asthmatic airways. J Allergy Clin Immunol. 2016;137:1398–405.
61. Huang YJ, Nelson CE, Brodie EL, Desantis TZ, Baek MS, Liu J, et al. Airway
microbiota and bronchial hyperresponsiveness in patients with suboptimally
controlled asthma. J Allergy Clin Immunol. 2011;127:372–81.
62. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD. Asthma-associated
differences in microbial composition of induced sputum. J Allergy Clin
Immunol. 2013;131:346–52.
63. Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DF, Arron JR, et al. The airway
microbiome in patients with severe asthma: associations with disease
features and severity. J Allergy Clin Immunol. 2015;136:874–84.
64. Carr TF, Kraft M. Chronic infection and severe asthma. Immunol Allergy Clin
N Am. 2016:36483–502.
65. Wong EH, Porter JD, Edwards MR, Johnston SL. The role of macrolides
in asthma: current evidence and future directions. Lancet Respir Med.
2014;2:657–70.
66. Slater M, Rivett DW, Williams L, Martin M, Harrison T, Sayers I, et al. The
impact of azithromycin therapy on the airway microbiota in asthma. Thorax.
2014;69:673–4.
67. Biesbroek G, Tsivtsivadze E, Sanders EA, Montijn R, Veenhoven RH, Keijser BJ,
et al. Early respiratory microbiota composition determines bacterial
succession patterns and respiratory health in children. Am J Respir Crit Care
Med. 2014;190:1283–92.
68. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant
nasopharyngeal microbiome impacts severity of lower respiratory infection
and risk of asthma development. Cell Host Microbe. 2015;17:704–15.
69. Stiemsma LT, Turvey SE. Asthma and the microbiome: defining the critical
window in early life. Allergy Asthma Clin Immunol. 2017;13:3.
70. Burbank AJ, Sood AK, Kesic MJ, Peden DB, Hernandez ML. Environmental
determinants of allergy and asthma in early life. J Allergy Clin Immunol.
2017;140:1–12.
71. Ong MS, Umetsu DT, Mandl KD. Consequences of antibiotics and infections
in infancy: bugs, drugs, and wheezing. Ann Allergy Asthma Immunol. 2014;
112:441–5.
72. Singanayagam A, Ritchie AI, Johnston SL. Role of microbiome in the
pathophysiology and disease course of asthma. Curr Opin Pulm Med.
2017;23:41–7.
73. Esposito S, Principi N. Impact of nasopharyngeal microbiota on the
development of respiratory tract diseases. Eur J Clin Microbiol Infect Dis.
2017;doi:https://doi.org/10.1007/s10096-017-3076-7. [Epub ahead of print].
74. Sokolowska M, Chen LY, Liu Y, Martinez-Anton A, Logun C, Alsaaty S, et al.
Dysregulation of lipidomic profile and antiviral immunity in response to
hyaluronan in patients with severe asthma. J Allergy Clin Immunol. 2017;
139:1379–83.
75. Vissing NH, Chawes BL, Bisgaard H. Increased risk of pneumonia and
bronchiolitis after bacterial colonization of the airways as neonates. Am J
Respir Crit Care Med. 2013;188:1246–52.
Sokolowska et al. Asthma Research and Practice  (2018) 4:1 Page 8 of 9
76. de Steenhuijsen Piters WA, Heinonen S, Hasrat R, Bunsow E, Smith B,
Suarez-Arrabal MC, Chaussabel D, et al. Nasopharyngeal microbiota, host
Transcriptome, and disease severity in children with respiratory Syncytial
virus infection. Am J Respir Crit Care Med. 2016;194:1104–15.
77. Mansbach JM, Hasegawa K, Henke DM, Ajami NJ, Petrosino JF, Shaw CA, et
al. Respiratory syncytial virus and rhinovirus severe bronchiolitis are
associated with distinct nasopharyngeal microbiota. J Allergy Clin Immunol.
2016;137:1909–13.
78. van den Bergh MR, Biesbroek G, Rossen JW, de Steenhuijsen Piters WA,
Bosch AA, van Gils EJ, et al. Associations between pathogens in the upper
respiratory tract of young children: interplay between viruses and bacteria.
PLoS One. 2012;7:e47711.
79. Bosch AA, Levin E, van Houten MA, Hasrat R, Kalkman G, Biesbroek G, et al.
Development of upper respiratory tract microbiota in infancy is affected by
mode of delivery. E Bio Med. 2016;9:336–45.
80. Hasegawa K, Linnemann RW, Mansbach JM, Ajami NJ, Espinola JA, Fiechtner
LG, et al. Household siblings and nasal and fecal microbiota in infants.
Pediatr Int. 2017;59:473–81.
81. Chiu CY, Chan YL, Tsai YS, Chen SA, Wang CJ, Chen KF, et al. Airway
microbial diversity is inversely associated with mite-sensitized rhinitis and
asthma in early childhood. Sci Rep. 2017;7:1820.
82. Jatzlauk G, Bartel S, Heine H, Schloter M, Krauss-Etschmann S. Influences of
environmental bacteria and their metabolites on allergies, asthma, and host
microbiota. Allergy. 2017;72:1859–67.
83. Birzele LT, Depner M, Ege MJ, Engel M, Kublik S, Bernau C, Loss GJ, et al.
Environmental and mucosal microbiota and their role in childhood asthma.
Allergy. 2017;72:109–19.
84. Depner M, Ege MJ, Cox MJ, Dwyer S, Walker AW, Birzele LT, et al. Bacterial
microbiota of the upper respiratory tract and childhood asthma. J Allergy
Clin Immunol. 2017;139:826–34.
85. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrländer
C, et al. Exposure to environmental microorganisms and childhood asthma.
N Engl J Med. 2011;364:701–9.
86. Lyons A, O'Mahony D, O'Brien F, MacSharry J, Sheil B, Ceddia M, et al.
Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective
in murine allergy models. Clin Exp Allergy. 2010;40:811–9.
87. Van De Pol M, Lutter R, Smids B, Weersink E, Van Der Zee J. Synbiotics
reduce allergen-induced T-helper 2 response and improve peak expiratory
flow in allergic asthmatics. Allergy. 2010;66:39–47.
88. Lee SC, Yang YH, Chuang SY, Huang SY, Pan WH. Reduced medication use
and improved pulmonary function with supplements containing vegetable
and fruit concentrate, fish oil and probiotics in asthmatic school children: a
randomised controlled trial. Br J Nutr. 2013;110:145–55.
89. Bieber T, Akdis C, Lauener R, Traidl-Hoffmann C, Schmid-Grendelmeier P,
Schappi G, et al. Global allergy forum and 3rd Davos declaration 2015:
atopic dermatitis/eczema: challenges and opportunities toward precision
medicine. Allergy. 2016;71:588–92.
90. Gray L, O’Hely M, Ranganathan S, Sly P, Vuillermin P. The maternal diet, gut
bacteria, and bacterial metabolites during pregnancy influence offspring
asthma. Front Immunol. 2017;8:365.
91. Bakker G, Nieuwdorp M. Fecal microbiota transplantation: therapeutic
potential for a multitude of diseases beyond Clostridium Difficile. Microbiol
Spectr. 2017;5
92. Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M, et al. Cancer
and the gut microbiota: an unexpected link. Sci Transl Med. 2015;7:271ps1.
93. Sivan A, Corrales L, Hubert N, Williams J, Aquino-Michaels K, Earley Z, et al.
Commensal Bifidobacterium promotes antitumor immunity and facilitates
anti-PD-L1 efficacy. Science. 2015;350:1084–9.
94. Barcik W, Wawrzyniak M, Akdis CA, O'Mahony L. Immune regulation by
histamine and histamine-secreting bacteria. Curr Opin Immunol. 2017;48:
108–13.
95. Durack J, Lynch S, Nariya S, Bhakta N, Beigelman A, Castro M, et al.
Features of the bronchial bacterial microbiome associated with atopy,
asthma, and responsiveness to inhaled corticosteroid treatment. J
Allergy Clin Immunol. 2017;140:63–75.
96. Ozturk A, Turturice B, Perkins D, Finn P. The potential for emerging
microbiome-mediated therapeutics in asthma. Curr Allergy Asthma Rep.
2017;17:62.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sokolowska et al. Asthma Research and Practice  (2018) 4:1 Page 9 of 9
